+91 80 2808 2808

Biocon Facilities complete Pre Approval U.S. FDA lnspection

  • Posted by: BIOCON


Company Statement

Bengaluru, India, Feb 18, 2019

“This is to inform you that the U.S. FDA concluded two pre approval inspections of Biocon’s manufacturing facilities in Bengaluru.

There were no observations and no Form 483 was issued after the pre-approval inspection of our Oral Solid Dosage Facility conducted between 11th-15th Feb 2019.

The pre-approval inspection of our additional, new injectable manufacturing line for a biologic drug product, conducted between 7th-15th Feb 2019, resulted in a form 483 with two observations. Biocon intends to address these expeditiously.

We remain committed to global standards of Quality and Compliance.”

– Company Spokesperson

Author: BIOCON
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>